Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
https://dxm-atlas.org/en/interactions/fluoxetine-paroxetine/
CompareKey points for this combination
General concepts in this text
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
Serotonin
A neurotransmitter: a substance that carries a chemical signal from a nerve cell.
There are different serotonin receptors in the brain and other parts of the body. The response to the signal depends on the receptor and its location.
Sources: Serotonin
- OpenStax: Neural Communication · Introduction to Behavioral Neuroscience, published 2024-11-13
- OpenStax: Neurotransmitters Made from Amino Acids — Serotonin · Introduction to Behavioral Neuroscience, published 2024-11-13
Drug exposure
Description of how much of a medicine is present in the body, using its concentrations.
Cmax describes the concentration peak; AUC combines concentrations over time.
Sources: Drug exposure
- FDA: Examples of Drugs that Interact with CYP Enzymes and Transporter Systems · Live institutional page read 2026-10-13; separate revision label unavailable
How well is this understood?
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
Can the amount reaching the body change?
ⓘ
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
- CYP2D6 inhibition persistence after discontinuation → In a fluoxetine study using DXM as a probe, CYP2D6 inhibition persisted for two weeks after fluoxetine was discontinued [50]. Finding below: Finding [50]
How can the effects add up?
ⓘ
SERT
A transporter protein involved in serotonin reuptake.
Inhibiting transport differs from acting on receptors.
Sources: SERT
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
What remains unknown?
Study times describe the endpoint studied; label intervals are tied to the product and direction of prescribing.
Sources
Check the review’s wording
- [2] AUVELITY prescribing information · Open publication
- [4] NUEDEXTA prescribing information · Open publication
- [50] Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe · Open publication
Evidence and sources
Research publication
[50] · Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe · 2001
Finding [50]
- What was found?
In a fluoxetine study using DXM as a probe, CYP2D6 inhibition persisted for two weeks after fluoxetine was discontinued [50].
CYP2D6 inhibition persistence after discontinuation
2 weeks
- What limits this finding?
Study times describe the endpoint studied; label intervals are tied to the product and direction of prescribing.
Scientific review: Persistent interactions after subjective effects have ended